On Day 3 after injection of TTI-621, the patient noted a 20% reduction in the size of the injected tumor. There was a decrease in the percentage of Sézary cells (CD4+CD26-) in the peripheral blood from 56.2% before injection of TTI-621 to 26.9% on Day 3 and 5.8% on Day 5. These changes were accompanied by a transient increase in CD11b+CD14+ macrophages in the peripheral blood from 3.9% before injection to 6.1% on Day 3, which returned to baseline by Day 7. The administration of PEGylated Interferon-a2a on day 7 after TTI-621 decreased the Sézary cell count from 52.5% to 0.62% on day 14, which was accompanied by an improvement in erythroderma as well as the resolution of dysesthesia of the skin that patient experienced at baseline. A significant increase in the percentage of NK cells (CD56+CD3-) and naïve CD8+ cells (CCR7+CD45RO-) was observed following injection of TTI-621 by day 7, and also observed 7 days after PEGylated Interferon-a2a. One week following the injection of PEGylated Interferon-a2a, all tumors had regressed completely.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM